Hepion Pharmaceuticals
Stock Forecast, Prediction & Price Target
Hepion Pharmaceuticals Financial Estimates
Hepion Pharmaceuticals Revenue Estimates
Hepion Pharmaceuticals EBITDA Estimates
Hepion Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | |
Net Income
% change YoY
| $-32.72M N/A | $-42.20M -28.96% | $-48.92M -15.93% | Avg: $-76.08M Low: $-24.81M High: $-24.81M avg. -55.51% | Avg: $-90.49M Low: $-37.48M High: $-37.48M avg. -18.94% | Avg: $-37.16M Low: $-37.16M High: $-37.16M avg. 58.93% | |
EBITDA
% change YoY
| $-30.31M N/A | $-43.54M -43.61% | $-49.25M -13.13% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | |
EPS
% change YoY
| -$9.31 N/A | -$11.07 -18.90% | -$12.32 -11.29% | Avg: -$6.25 Low: -$6.25 High: -$6.25 avg. 49.26% | Avg: -$9.44 Low: -$9.44 High: -$9.44 avg. -51.04% | Avg: -$9.36 Low: -$9.36 High: -$9.36 avg. 0.84% | |
Operating Expenses
% change YoY
| $30.40M N/A | $43.61M 43.46% | $48.44M 11.07% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% | Avg: $0 Low: $0 High: $0 avg. 0% | |
FAQ
What is Hepion Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -5.17% in 2025-2027.
We have gathered data from 1 analysts. Their low estimate is -24.81M, average is -76.08M and high is -24.81M.
What is Hepion Pharmaceuticals stock revenue growth forecast?
We have gathered data from 1 analysts. Their low revenue estimate is N/A, average is N/A and high is N/A.
What is Hepion Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -0.30% in 2025-2027.
We have gathered data from 1 analysts. Their low earnings per share estimate is -$6.25, average is -$6.25 and high is $-6.25.
What is the best performing analyst?
In the last twelve months analysts have been covering Hepion Pharmaceuticals stock. The most successful analyst is Kristen Kluska whose win rate is 100%. He has correctly predicted 1/1 price targets.